New combo therapy targets tough melanoma
NCT ID NCT02721459
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 28 times
Summary
This early-phase study tests a new drug called XL888 added to two standard melanoma drugs (vemurafenib and cobimetinib) for people with advanced BRAF-mutated melanoma that cannot be removed by surgery. The main goal is to find the safest dose of XL888 and see how well the combination is tolerated. About 26 adults with stage III or IV melanoma are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.